Trends, Challenges and a Reshaped Global Deal Landscape
Global pharmaceutical deal value soared to a record USD 275.1 billion in 2025, with Chinese companies creating nearly half of that value.
As outbound licensing activity accelerates, global pharma companies are competing fiercely for high-potential assets while facing mounting pressure to execute increasingly complex cross-border deals faster, manage diligence at scale and modernize outdated workflows.
Read the report to learn:
- How China emerged as a driving force in global pharma dealmaking
- Why big-ticket licensing deals are surging in the region
- Which therapies and modalities are attracting the highest bids
- How diligence-ready targets are gaining a competitive edge
- Technology’s role in executing cross-border deals
